Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

WALTHAM, Mass., Sept.  05, 2019  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Senior Vice President of Clinical Development and Medical Affairs, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, which is being held September 8-10 in New York. Management is scheduled to present on Tuesday, September 10 from 9:10-9:35am ET.

Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Chiasma (CHMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chiasma (CHMA) Upgraded to Buy: Here's Why

Chiasma's (CHMA) CEO Raj Kannan on Q2 2019 Results - Earnings Call Transcript

Chiasma announced positive results from its Phase 3 CHIASMA OPTIMAL study in that all primary and secondary endpoints were met.

Chiasma Intends To Redeem Itself With Multiple Catalysts In The Coming Months

Further expanding his holdings in the health care space, billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.24% stake in biotech company Chiasma Inc.

Steven Cohen Charges Into Chiasma

CHMA chart shows a strong bullish trend in the last one year, however, the stock is down strongly in the past few days after the end of profit taking session.

Chiasma: An Interesting Bet Despite The Recent Spike

Thinly-traded micro-cap biotech Chiasma Inc (NASDAQ: CHMA) is advancing strongly in reaction to a clinical trial readout from the company.

Here Is What's Driving The Rally In Chiasma

Chiasma is a small-cap biotech focusing on developing of oral formulation of the existing drug for acromegaly (octreotide) and attacking a $810m market.

Chiasma: Some Derisking Based On Previous CRL

Chiasma (CHMA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%

As of late, it has definitely been a great time to be an investor Chiasma.

News for Chiasma Stock (CHMA)